Controlled-Release Basic Fibroblast Growth Factor for Peripheral Artery Disease: Comparison with Autologous Bone Marrow-Derived Stem Cell Transfer

Authors:

Abstract
Objective: We examined the safety and efficacy of controlled-release basic fibroblast growth factor (b-FGF) for peripheral artery disease (PAD), compared with autologous bone marrow mononuclear cell implantation (BMCI). Background: We recently developed a b-FGF-incorporated biodegradable hydrogel that enables slow-releasing drug delivery system. Methods: PAD patients were divided into a b-FGF group (n=10) and BMCI group (n=15). Injection of gelatin hydrogel containing 600 μg b-FGF or BMCI (0.4–5.1×1010 cell) was performed. Visual analog pain scale (VAS), 99mtechnetium-tetrofosmin (Tc-TF) scintigraphy, transcutaneous oxygen tension (TcPO2), and ankle-brachial index (ABI) were evaluated before and 4 weeks after each treatment, and 2-year prognosis was determined. Results: VAS (b-FGF 67±15 to 4±5, pp2 (b-FGF 16±14 to 47±17, ppConclusion: Controlled-release b-FGF is as safe as BMCI, and its efficacy appears to be comparable. Thus, this therapy may be an alternative to BMCI.

This publication has 30 references indexed in Scilit: